Intriguingly, the Lyn overexpression has also been reported in primary CML cells with imatinib resistance and in primary CLL cells and implicated in proliferation and survival of these cells through the increased kinase activity [10], [27]. This evidence concerns the gene LYN and chronic myelogenous leukemia, BCR-ABL1 positive.